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all diagnoses was 146, 149, and 114 days for olanzapine,
risperidone and quetiapine respectively. Mean duration of
therapy varied widely by diagnostic conditions (190, 202
& 171 days for schizoaffective disorder, 146, 131 & 121
days for PTSD all for olanzapine, risperidone and queti-
apine respectively). Concomitant use of more than one
atypical antipsychotic medication occurred in 17–25% of
patients, and most commonly with quetiapine. Concomi-
tant use of any other psychotropic medication was similar
in subjects receiving risperidone, olanzapine, and queti-
apine (85, 86, 85% respectively). Twenty-two percent of
patients switched atypical therapy at some point during
the study period. Of patients who had received therapy
for at least 10 weeks and switched atypical, the most
common switching occurred from olanzapine to quetiap-
ine (48%). CONCLUSIONS: Dosing and duration of
therapy of atypical antipsychotics in the Cleveland VA
varies widely between diagnostic conditions.
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OBJECTIVE: Time to treatment discontinuation for any
cause was previously identiﬁed as an important outcome
parameter in the medication management of schizophre-
nia. This study compared four antipsychotics—olanzap-
ine, risperidone, quetiapine, and haloperidol—on the time
to all-cause discontinuation. METHODS: Participants (N
= 964) were new initiators of olanzapine, risperidone,
quetiapine or haloperidol in the Schizophrenia Care and
Assessment Program (SCAP), a 3-year longitudinal,
observational study of schizophrenia. Time to all-cause
discontinuation of the antipsychotic during the 1 year fol-
lowing its initiation was measured by a) the total number
of days on the antipsychotic, and b) the number of days
of continuous treatment up to the ﬁrst gap of >14 days.
Analyses employed Mantel-Haenszel and Cox propor-
tional hazard model. Results were further conﬁrmed
using a mixed model approach. RESULTS: Olanzapine-
treated patients were on their medication signiﬁcantly
longer than patients receiving risperidone, quetiapine, or
haloperidol. Compared with olanzapine, the likelihood 
of discontinuation was 26%, 54%, and 158% greater
among patients receiving risperidone, quetiapine, or
haloperidol, respectively. CONCLUSION: Antipsy-
chotics were found to signiﬁcantly differ in the time to
all-cause discontinuation, such that olanzapine-treated
patients evidenced the longest time to discontinuation,
followed by risperidone, quetiapine, and haloperidol.
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OBJECTIVES: Recent changes to the formulary status 
of selective serotonin reuptake inhibitors (SSRIs) at our
institution, notably the removal of sertraline and avail-
ability of generic ﬂuoxetine, have altered the selection of
the most cost-effective SSRI. Objective of this protocol is
to evaluate the effect of physician proﬁling and academic
detailing on the utilization and cost of SSRIs in a staff-
model managed care organization. METHODS: A retro-
spective review of 71,801 SSRI pharmacy prescription
claims was performed for CY 2002. Following removal
of sertraline from the formulary (average monthly copay-
ment increased from $20 to $43 after removal), a volun-
tary program to encourage conversion to a formulary
alternative (paroxetine, citalopram, or generic ﬂuoxetine)
was initiated. A physician prescribing report program,
supplemented with academic detailing, was implemented
highlighting SSRI utilization and formulary and pricing
concerns. Prescriptions, patients (utilizing members), and
drug costs were measured. RESULTS: In January 2002,
the number of prescriptions was 2537 (44.9% of SSRI
market share) and 1186 (21%) for sertraline and generic
ﬂuoxetine, respectively. By December 2002, the corre-
sponding prescription numbers were 1039 (16.5%) and
2601 (41.7%). For CY 2002, the number of utilizing
members for sertraline decreased from 2415 to 982 and
increased from 1116 to 2454 for generic ﬂuoxetine. 
Prescription claims for other SSRIs remained relatively
constant. Net health plan savings in CY 2002 were
$584,369, primarily as a result of the conversion from
sertraline to generic ﬂuoxetine. CONCLUSIONS: Al-
though conversion of sertraline to non-formulary status
greatly assisted in this program, a signiﬁcant industry-
based marketing effort also began to direct those patients
to either paroxetine or citalopram ($20 monthly copay-
ments for each). However, the combination of physician
proﬁling and academic detailing was associated with an
increase in utilization of less-expensive generic ﬂuoxetine
as opposed to further gains by other formulary SSRIs.
Estimated annual savings for CY 2003, based on current
SSRI utilization, are at least $975,536.
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OBJECTIVE: To set up regional assistant systems, inte-
grate health resources and advocate high-quality health
service, Department of Health in Taiwan promotes the
4th Health Network-New Era Health Care Program in
central of Taiwan. One of the major issues is to promote
public health education. We set up an educational
program to promote appropriate medication concept 
to the public and students in communities in central 
of Taiwan. METHODS: Supported by Department of
Health and conducted for one year, this was a prospec-
tive program consisting of training workshops for 
community pharmacists, developing and implementing
surveys, and public educational promotion. The major
issues of public educational promotions include appro-
priate use of medication, especially those about general
medication use, antimicrobial agents and being alert
against drug abuse. Even though 34 community pharma-
cists were recommended from four pharmacy associations
in central Taiwan and participated in the training work-
shops, only 8 pharmacists were qualiﬁed as instructor
pharmacists according to the results of questionnaire and
realistic demonstration after training and evaluating.
During 3 months, we held 13 promotions; 6 of them were
held in communities and 7 in schools. To evaluate the out-
comes of promotions, we conducted a pre- and post-
promotion survey via questionnaires. Questionnaires
included general information, medication information
resources and medication knowledge. RESULTS: A total
of 226 participates in communities were distributed with
115 post-promotion survey (51%) and of 475 partici-
pates in schools were distributed with 410 (86%) post-
promotion survey. The pre-promotion results showed
that 57.07% community participators and 77.48% 
students got medication information from more than 2
sources. After promotions, the results showed that med-
ication knowledge improved signiﬁcantly in schools and
community participators (p < 0.05). CONCLUSIONS:
We can ﬁnd out that it sure is a good opportunity for
pharmacists to contact the public through well-designed
promotion activities and beneﬁt the healthcare systems.
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OBJECTIVES: Anxiety disorders are among the most
common mental health conditions in the United States but
study of their impact on labor productivity has been
limited. The objective of this study was to estimate the
annual indirect costs due to anxiety disorders in the U.S.
population. METHODS: Retrospective analysis was con-
ducted of the 1999 Medical Expenditure Panel Survey
(MEPS). The MEPS provided data from a nationally 
representative sample of 24,618 respondents and their
medical care and health insurance providers and employ-
ers. Data extracted for this study included medical con-
ditions and employment information comprised of hourly
earnings, hours worked per week, and disability days.
Anxiety disorders were deﬁned using the current Diag-
nostic and Statistical Manual of Mental Disorders (DSM-
IV-TR) and were mapped to corresponding ICD-9-CM
codes and included anxiety and panic disorders, stress
disorders, obsessive compulsive disorder, and phobias.
Patients with an anxiety disorder who incurred absence
from work were identiﬁed using ICD-9-CM codes and
variables denoting disability days. Indirect costs were 
calculated for patients who missed workdays using the
human capital approach. Sample estimates were weighted
and projected to the population and 95% conﬁdence
limits were calculated using the Taylor expansion
method. RESULTS: As a percentage of the population,
the number of patients with an anxiety disorder who
missed workdays was low, at 0.20 percent (95% CL =
0.13 to 0.27). However, the associated indirect costs were
substantial, estimated at $2,981,633,568. Mean indirect
costs were $5347 per patient who missed workdays. Rel-
ative to the entire population, mean indirect costs per
person were $10.79. CONCLUSIONS: Although the
prevalence of anxiety disorders resulting in absenteeism
was found to be relatively low, the corresponding losses
in productivity were almost $3 billion. This suggests long-
term disability associated with these conditions and high-
lights the importance of early diagnosis and treatment to
minimize work loss.
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OBJECTIVES: To compare “homeopathic drugs” 
strategy (strategy H) with “psychotropic drugs” strategy
(strategy P) for treating anxiety disorders in France, 
in terms of effectiveness, satisfaction, and costs.
METHODS: Effectiveness, satisfaction, and economic
data were derived from a 3-month pragmatic prospective
study including 394 patients which were “male or 
female over 18, who consulted a homeopathic or non-
homeopathic GP for the ﬁrst time for symptoms of
anxiety disorders such as deﬁned by the DSM IV”. Strat-
egy H included 135 patients that received at least one
homeopathic drug and no psychotropic drugs, and strat-
egy P 185 patients that received at least one psychotropic
drug and no homeopathic drugs. In both strategies, other
drugs could have been prescribed (trace elements, etc).
Effectiveness was assessed by GPs using the “Hamilton
Anxiety Scale”, and by patients using the “Spielberger
State Trait Anxiety Inventory.” Satisfaction of GPs and
